U.S. Food and Drug Administration
Dr. Sandhya Sanduja is currently a Team Leader in the Pharmacology/Toxicology branch of FDA/CBER/OTAT. Her duties include review of nonclinical data to inform regulatory and policy decisions for CBER advanced therapy products. Prior to joining the FDA, she was a postdoctoral fellow at the Whitehead Institute of MIT. Dr. Sanduja received her BS in Microbiology from Gargi College, New Delhi, India (2003), MS in Biotechnology from Jawaharlal Nehru University (2005) and Ph.D. in Biological Sciences (2011) from University of South Carolina, Columbia. Dr. Sanduja has authored/co-authored several high-impact, peer-reviewed publications in leading biomedical journals, and received research grants from American Association for University Women (AAUW). She served on reviewer boards for PLOS ONE, Tumor Biology, and WIREs RNA and on the editorial board of Gastrointestinal Cancer. She is a member of the American Society of Gene and Cell Therapy.
Wednesday, October 28, 2020
10:30 AM – 11:00 AM ET